USA Dominates Alzheimer’s Disease Drugs Market, States iGATE Research in Its New Report Now Available at MarketPublishers.com
17 Jul 2017 • by Natalie Aster
LONDON – With the world population ageing, the number of patients having Alzheimer’s disease is poised to grow in the offing. Alzheimer's disease drugs market is a high reward and high risk one. Currently marketed drugs have reached maturity; and the patents of leading drugs have expired. The present-day unmet needs open up a great opportunity for pharmacos that are developing new targeted therapies.
In 2016, the medicines such as Namenda (Memantine), Memary, Aricept (donepezil) and Exelon (rivastigmine) dominated the global Alzheimer’s disease drugs market. The market share of these 4 drugs accounted for 80% in the same year.
Amid the other prominent drug products in the market one can name Ebixa, Rivastach and Nootropil and Razadyne/Reminyl.
As the patents of popular drug products expire, the sales of the Alzheimer’s drugs also tend to decline. Meantime, there are some pipeline drugs such as Crenezumab, Gantenerumab and Aducanumab, amid others, that are projected to hit the market through to 2020.
Geography-wise, the USA takes the lead in the market, with Japan and China occupying the second and third positions, respectively, as of 2016. The EU5 nations together captured more than 10% of the overall Alzheimer’s disease drugs marketplace in 2016.
Topical report “Global Alzheimer’s Disease Drugs Market, Regional Analysis & Forecast, Major Deals & Funding, and Pipeline Drugs Analysis to 2021” elaborated by iGATE Research is designed to provide a detailed, unprejudiced analysis of the market on a global level with a focus on the 9 major national markets.
The study provides an analysis of the sales of the 9 major Alzheimer’s disease drugs as well as offers detailed forecasts; includes data on the 3 pipeline drug product sales and offer respective forecast figures. It includes detailed country-wise market analysis and forecast, sheds light on the prevalence rates of the disease across the countries discussed plus detailed forecasts; includes a list of pipeline drugs in different stages of development; tacks the key deals in Alzheimer’s disease drugs marketplace; covers investment in the respective domain R&D; canvasses key market drivers and challenges.
More new reports by our partner can be found at the iGATE Research page.